Clinical and scientific aspects related to biosimilars in inflammatory bowel diseases (IBD): position document of the Belgian IBD Research & Development Group (BIRD)

Vermeire, Séverine; Louis, E; Dewit, O; Franchimont, D; Moreels, T; Ferrante, Marc; Rahier, J-F; Van Hootegem, Philippe; De Vos, M; Mana, F; Baert, F

Clinical and scientific aspects related to biosimilars in inflammatory bowel diseases (IBD): position document of the Belgian IBD Research & Development Group (BIRD)

Author:

Vermeire, Séverine

Louis, E ; Dewit, O ; Franchimont, D ; Moreels, T ; Ferrante, Marc ; Rahier, J-F ; Van Hootegem, Philippe ; De Vos, M ; Mana, F ; Baert, F

Keywords:

Science & Technology, Life Sciences & Biomedicine, Gastroenterology & Hepatology, biosimilar, Crohn's disease, ulcerative colitis, inflammatory bowel disease, anti-TNF, INNOVATOR INFLIXIMAB, PARALLEL-GROUP, DOUBLE-BLIND, STATEMENT, EFFICACY, SAFETY, CT-P13, Adalimumab, Antibodies, Monoclonal, Antirheumatic Agents, Arthritis, Rheumatoid, Belgium, Biosimilar Pharmaceuticals, Drug Approval, Gastrointestinal Agents, Humans, Inflammatory Bowel Diseases, Infliximab, Tumor Necrosis Factor-alpha, Belgian IBD Research & Development (BIRD), 1103 Clinical Sciences, 3202 Clinical sciences